Compare Domino's Pizza, Inc. (DPZ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Novartis AG — how do they compare? Domino's Pizza, Inc. trades at $355.78 (market cap $11.51B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 25.9× Domino's Pizza, Inc.'s market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| DPZ | NVS | |
|---|---|---|
Market Cap | $11.51B | $298.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $467.30 | $168.62 |
52-Week Low | $282.89 | $119.31 |
Enterprise Value | $16.47B | $339.50B |
Dividend Yield | 2.29% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $350.95, down 2.09% on the day, with a bullish technical signal supported by moving averages and ADX. The company reported Q2 2026 EPS of $4.07, missing estimates, but revenue growth remains steady, with 2025 revenue at $4.94B and net income of $601.70M. Recent news highlights Domino's beta testing a new website and app with customer incentives, while institutional positions show mixed adjustments.
The outlook is mixed: analyst consensus is a Moderate Buy with a $371.67 price target, implying upside, but near-term risks include weaker ticket trends, margin pressure from rising costs, and consecutive EPS misses. High debt levels and insider selling add caution, though operational cash flow strength and brand initiatives support long-term potential.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
